Biogen, Ionis End Development of ALS Candidate After Study Failure
March 28 2022 - 8:31AM
Dow Jones News
By Colin Kellaher
Biogen Inc. and Ionis Pharmaceuticals Inc. on Monday said they
are ending development of a drug candidate for a form of
amyotrophic lateral sclerosis, the paralyzing condition commonly
known as Lou Gehrig's disease, following the failure of a Phase 1
study.
The companies said BIIB078 didn't show a clinical benefit in
patients with C9orf72-associated ALS and didn't meet any secondary
efficacy endpoints.
Biogen and Ionis said the primary objective of the study was to
assess safety and tolerability, and BIIB078 was generally
well-tolerated. The companies said they remain committed to their
work advancing ALS research and developing therapies for all forms
of the disease, and the study results will inform future
research.
Cambridge, Mass., drugmaker Biogen and Ionis, a Carlsbad,
Calif., pharmaceutical company, have collaborated on neurology
drugs since 2012.
Shares of Ionis, which closed Friday at $36.67, fell 4.5% in
premarket trading. Biogen shares slipped 0.6%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 28, 2022 08:16 ET (12:16 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Apr 2024 to May 2024
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From May 2023 to May 2024
